Somatic and novel pharmacological treatments

Gary M. Hasey, Glen Xiong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Borderline personality disorder (BPD) is often comorbid with major depressive disorder and associated with more frequent hospitalizations, more extensive use of psychiatric resources and greater treatment-resistance compared to other personality disorders. Discussion of the entire range of somatic and pharmacological options that might be considered in the treatment-resistant patient with BPD is beyond the scope of this short chapter. We therefore limit our review to those more novel treatment modalities that we believe are either the most viable or the most topical for BPD given the information available at this time. We will focus on the treatment of the complex, seriously ill geriatric patient, typically diagnosed with comorbid psychiatric pathology and requiring treatment in an institutional setting. In the section on somatic therapies we discuss electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS). In the section on pharmacotherapies we discuss ketamine infusion and L-methylfolate. We conclude that ECT, rTMS and L-methylfolate could be useful treatment modalities for the complicated patient with BPD, particularly if there is comorbid major depressive disorder. DBS is highly invasive and the evidence supporting its utility for major depressive disorder is being questioned. The beneficial effect of ketamine is brief; the drug must be administered intravenously and can produce dissociation and cardiovascular effects that may be problematic for the geriatric patient with BPD.

Original languageEnglish (US)
Title of host publicationBorderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings
PublisherNova Science Publishers, Inc.
Pages111-121
Number of pages11
ISBN (Electronic)9781634822305
ISBN (Print)9781634822213
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Borderline Personality Disorder
Pharmacology
Major Depressive Disorder
Electroconvulsive Therapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation
Ketamine
Geriatrics
Therapeutics
Psychiatry
Dissociative Disorders
Personality Disorders
Hospitalization
Pathology
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychology(all)
  • Medicine(all)

Cite this

Hasey, G. M., & Xiong, G. (2015). Somatic and novel pharmacological treatments. In Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings (pp. 111-121). Nova Science Publishers, Inc..

Somatic and novel pharmacological treatments. / Hasey, Gary M.; Xiong, Glen.

Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings. Nova Science Publishers, Inc., 2015. p. 111-121.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hasey, GM & Xiong, G 2015, Somatic and novel pharmacological treatments. in Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings. Nova Science Publishers, Inc., pp. 111-121.
Hasey GM, Xiong G. Somatic and novel pharmacological treatments. In Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings. Nova Science Publishers, Inc. 2015. p. 111-121
Hasey, Gary M. ; Xiong, Glen. / Somatic and novel pharmacological treatments. Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings. Nova Science Publishers, Inc., 2015. pp. 111-121
@inbook{f745cf3753bc416fa9ba652a1b8d020f,
title = "Somatic and novel pharmacological treatments",
abstract = "Borderline personality disorder (BPD) is often comorbid with major depressive disorder and associated with more frequent hospitalizations, more extensive use of psychiatric resources and greater treatment-resistance compared to other personality disorders. Discussion of the entire range of somatic and pharmacological options that might be considered in the treatment-resistant patient with BPD is beyond the scope of this short chapter. We therefore limit our review to those more novel treatment modalities that we believe are either the most viable or the most topical for BPD given the information available at this time. We will focus on the treatment of the complex, seriously ill geriatric patient, typically diagnosed with comorbid psychiatric pathology and requiring treatment in an institutional setting. In the section on somatic therapies we discuss electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS). In the section on pharmacotherapies we discuss ketamine infusion and L-methylfolate. We conclude that ECT, rTMS and L-methylfolate could be useful treatment modalities for the complicated patient with BPD, particularly if there is comorbid major depressive disorder. DBS is highly invasive and the evidence supporting its utility for major depressive disorder is being questioned. The beneficial effect of ketamine is brief; the drug must be administered intravenously and can produce dissociation and cardiovascular effects that may be problematic for the geriatric patient with BPD.",
author = "Hasey, {Gary M.} and Glen Xiong",
year = "2015",
month = "4",
day = "1",
language = "English (US)",
isbn = "9781634822213",
pages = "111--121",
booktitle = "Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Somatic and novel pharmacological treatments

AU - Hasey, Gary M.

AU - Xiong, Glen

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Borderline personality disorder (BPD) is often comorbid with major depressive disorder and associated with more frequent hospitalizations, more extensive use of psychiatric resources and greater treatment-resistance compared to other personality disorders. Discussion of the entire range of somatic and pharmacological options that might be considered in the treatment-resistant patient with BPD is beyond the scope of this short chapter. We therefore limit our review to those more novel treatment modalities that we believe are either the most viable or the most topical for BPD given the information available at this time. We will focus on the treatment of the complex, seriously ill geriatric patient, typically diagnosed with comorbid psychiatric pathology and requiring treatment in an institutional setting. In the section on somatic therapies we discuss electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS). In the section on pharmacotherapies we discuss ketamine infusion and L-methylfolate. We conclude that ECT, rTMS and L-methylfolate could be useful treatment modalities for the complicated patient with BPD, particularly if there is comorbid major depressive disorder. DBS is highly invasive and the evidence supporting its utility for major depressive disorder is being questioned. The beneficial effect of ketamine is brief; the drug must be administered intravenously and can produce dissociation and cardiovascular effects that may be problematic for the geriatric patient with BPD.

AB - Borderline personality disorder (BPD) is often comorbid with major depressive disorder and associated with more frequent hospitalizations, more extensive use of psychiatric resources and greater treatment-resistance compared to other personality disorders. Discussion of the entire range of somatic and pharmacological options that might be considered in the treatment-resistant patient with BPD is beyond the scope of this short chapter. We therefore limit our review to those more novel treatment modalities that we believe are either the most viable or the most topical for BPD given the information available at this time. We will focus on the treatment of the complex, seriously ill geriatric patient, typically diagnosed with comorbid psychiatric pathology and requiring treatment in an institutional setting. In the section on somatic therapies we discuss electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS). In the section on pharmacotherapies we discuss ketamine infusion and L-methylfolate. We conclude that ECT, rTMS and L-methylfolate could be useful treatment modalities for the complicated patient with BPD, particularly if there is comorbid major depressive disorder. DBS is highly invasive and the evidence supporting its utility for major depressive disorder is being questioned. The beneficial effect of ketamine is brief; the drug must be administered intravenously and can produce dissociation and cardiovascular effects that may be problematic for the geriatric patient with BPD.

UR - http://www.scopus.com/inward/record.url?scp=84956642700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956642700&partnerID=8YFLogxK

M3 - Chapter

SN - 9781634822213

SP - 111

EP - 121

BT - Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings

PB - Nova Science Publishers, Inc.

ER -